What is SmartLabs?
Headquartered in Boston, Massachusetts, SmartLabs specializes in the design, construction, and management of sophisticated research environments. The company addresses the logistical hurdles faced by organizations of all sizes by offering a comprehensive suite of services, including in-house architecture, construction management, and full-service facilities management. By providing shared amenities and modular lab spaces, SmartLabs effectively lowers the barrier to entry for emerging research firms while offering scalable solutions for established industry players. Its market position is defined by its ability to transform the traditional laboratory model into a service-oriented, agile infrastructure that supports the rapid pace of modern drug discovery and development.
How much funding has SmartLabs raised?
SmartLabs has raised a total of $387.8M across 4 funding rounds:
Angel/Seed
$8.8M
Series A
$81M
Series B
$250M
Series C
$48M
Angel/Seed (2015): $8.8M, investors not publicly disclosed
Series A (2020): $81M, investors not publicly disclosed
Series B (2021): $250M supported by Onex Falcon, Winslow Capital Management, Breed’s Hill Capital, Conversion Venture Capital, and ArrowMark Partners
Series C (2024): $48M featuring Winslow Capital Management, Conversion Venture Capital, and ArrowMark Partners
Key Investors in SmartLabs
Winslow Capital Management
Founded in 1992, Winslow Capital is a premier growth equity investment firm headquartered in Minneapolis, Minnesota.
Conversion Venture Capital
CVC2 is a private equity and venture capital firm that invests its own capital alongside management teams and entrepreneurs to build segment-leading businesses.
ArrowMark Partners
Established in 2007, ArrowMark Partners is an employee-owned asset manager with specialized expertise in alternative credit and growth equity asset classes.
What's next for SmartLabs?
With the successful closure of this major enterprise-level funding, SmartLabs is well-positioned to accelerate its national expansion and enhance its service offerings. The strategic capital will likely be deployed to scale its footprint in key biotech hubs, further optimizing its facility management technology and expanding its portfolio of shared research amenities. As the life sciences industry continues to prioritize capital efficiency and operational agility, SmartLabs is poised to solidify its status as an essential partner in the research ecosystem. Future growth will likely focus on deepening its integration with client workflows and potentially diversifying its facility types to accommodate a broader range of specialized scientific requirements.
See full SmartLabs company page
